Carl Ogas
Internal Medicine · Muskegon, MINPI 1467539940
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,755 and has fallen 85.0% since, to $263 in 2023. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 371 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AstraZeneca$541
- Amgen$520
- Philips North America LLC$365
- Bayer$342
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,92699%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 81 | $1,207 |
| Lilly USA, LLC | 88 | $1,185 |
| AstraZeneca | 30 | $541 |
| Amgen(2 entities) | 35 | $520 |
| Philips North America LLC | 12 | $365 |
| Bayer | 25 | $342 |
| Pfizer | 16 | $317 |
| Boehringer Ingelheim | 14 | $277 |
| AbbVie(2 entities) | 13 | $220 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $154 |
| Biohaven Pharmaceuticals, Inc. | 3 | $150 |
| Merck | 9 | $146 |
| Johnson & Johnson | 8 | $119 |
| GSK | 6 | $92 |
| Novartis | 5 | $67 |
| Radius Health, Inc. | 4 | $57 |
| Dexcom, Inc. | 1 | $23 |
| Medtronic | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$122
- Wegovy$108
How this compares
$6,012 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $21,329 |
| JardianceEmpagliflozin | 21 | $16,501 |
| TrulicityDulaglutide | 17 | $15,369 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $15,154 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 205 | $3,896 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,510 |
| Atorvastatin Calcium | 77 | $1,273 |
| Rosuvastatin Calcium | 31 | $1,080 |
| Pregabalin | 38 | $790 |
| Pantoprazole Sodium | 21 | $757 |
| Tamsulosin Hcl | 20 | $716 |
| Olmesartan Medoxomil | 40 | $692 |
| Methylphenidate Er (La)Methylphenidate Hcl | 11 | $609 |
| Metformin Hcl | 31 | $518 |
| Meloxicam | 68 | $426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $317 | $21,32929 claims |
| Boehringer IngelheimJardiance | $277 | $16,50121 claims |
| Lilly USA, LLCTrulicity | $1,185 | $15,36917 claims |
| GSKTrelegy Ellipta | $92 | $15,15421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Muskegon
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.